← FDA DRUG APPROVALS
FDA ANDA · ANDA203870
TRI FEMYNOR
norgestimate and ethinyl estradiol
Sponsor: NAARI PTE
APPLICATION
ANDA203870
TYPE
ANDA
ORIGINAL APPROVAL
2015-11-12
LATEST ACTION
2023-10-16
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
NORGESTIMATE AND ETHINYL ESTRADIOLDiscontinued
ETHINYL ESTRADIOL 0.035MG,0.035MG,0.035MG, NORGESTIMATE 0.18MG,0.215MG,0.25MG · TABLET · ORAL-28
Approval history
2023-10-16Labeling · Supplement 9 · standardAP
2023-10-16Labeling · Supplement 8 · standardAP
2022-04-29Labeling · Supplement 7 · standardAP
2015-11-12UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.